Evelo Biosciences (EVLO) Set to Announce Quarterly Earnings on Thursday

Evelo Biosciences (NASDAQ:EVLOGet Rating) will be releasing its earnings data before the market opens on Thursday, March 16th. Analysts expect Evelo Biosciences to post earnings of ($0.29) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Evelo Biosciences Price Performance

Shares of NASDAQ EVLO opened at $0.37 on Tuesday. Evelo Biosciences has a 1-year low of $0.36 and a 1-year high of $4.36. The company has a market cap of $39.91 million, a price-to-earnings ratio of -0.21 and a beta of 1.37. The company has a debt-to-equity ratio of 3.93, a current ratio of 2.69 and a quick ratio of 2.69. The stock’s 50-day moving average is $0.96 and its two-hundred day moving average is $1.64.

Hedge Funds Weigh In On Evelo Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of EVLO. Vanguard Group Inc. lifted its position in Evelo Biosciences by 9.4% in the first quarter. Vanguard Group Inc. now owns 1,544,518 shares of the company’s stock worth $5,235,000 after purchasing an additional 132,702 shares during the period. Cresset Asset Management LLC boosted its holdings in Evelo Biosciences by 200.0% during the first quarter. Cresset Asset Management LLC now owns 30,000 shares of the company’s stock valued at $102,000 after acquiring an additional 20,000 shares during the period. State Street Corp raised its position in shares of Evelo Biosciences by 3.3% during the first quarter. State Street Corp now owns 578,861 shares of the company’s stock valued at $1,962,000 after buying an additional 18,469 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Evelo Biosciences during the first quarter valued at about $38,000. Finally, Millennium Management LLC raised its position in Evelo Biosciences by 343.7% in the second quarter. Millennium Management LLC now owns 193,134 shares of the company’s stock worth $408,000 after purchasing an additional 149,605 shares in the last quarter. 85.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EVLO. Chardan Capital cut Evelo Biosciences from a “buy” rating to a “neutral” rating and set a $2.50 price objective for the company. in a research report on Wednesday, November 16th. Morgan Stanley dropped their price target on Evelo Biosciences from $4.00 to $2.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 15th. Finally, Jefferies Financial Group cut Evelo Biosciences from a “buy” rating to an “underperform” rating in a report on Wednesday, February 1st.

Evelo Biosciences Company Profile

(Get Rating)

Evelo Biosciences, Inc operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B.

Further Reading

Earnings History for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.